Baillie Gifford & CO Recursion Pharmaceuticals, Inc. Transaction History

Baillie Gifford & CO

$128 Billion
Q3 2025

A detailed history of Baillie Gifford & CO transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 23,978,695 shares of RXRX stock, worth $99.3 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

23,978,695

Previous 24,173,815 0.81%

Holding current value

$99.3 Million

Previous $122 Million 4.34%

% of portfolio

0.09%

Previous 0.1%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 31, 2025	SELL	$4.52 - $6.54 $881,942 - $1.28 Million	-195,120 Reduced 0.81%	23,978,695 $117 Million
Q2 2025 Aug 06, 2025	SELL	$3.97 - $5.84 $870,224 - $1.28 Million	-219,200 Reduced 0.9%	24,173,815 $122 Million
Q1 2025 May 07, 2025	SELL	$5.29 - $10.87 $2.49 Million - $5.12 Million	-471,043 Reduced 1.89%	24,393,015 $129 Million
Q4 2024 Jan 31, 2025	SELL	$5.7 - $8.27 $2.14 Million - $3.11 Million	-375,812 Reduced 1.49%	24,864,058 $168 Million
Q3 2024 Nov 05, 2024	SELL	$5.92 - $8.6 $7.99 Million - $11.6 Million	-1,350,066 Reduced 5.08%	25,239,870 $166 Million
Q2 2024 Jul 25, 2024	BUY	$7.35 - $10.05 $18.5 Million - $25.3 Million	2,522,132 Added 10.48%	26,589,936 $199 Million
Q1 2024 May 01, 2024	SELL	$9.13 - $15.52 $1.02 Million - $1.73 Million	-111,700 Reduced 0.46%	24,067,804 $240 Million
Q4 2023 Jan 26, 2024	SELL	$5.09 - $10.79 $1.89 Million - $4.01 Million	-371,905 Reduced 1.51%	24,179,504 $238 Million
Q3 2023 Nov 13, 2023	SELL	$6.59 - $15.86 $3.6 Million - $8.66 Million	-546,221 Reduced 2.18%	24,551,409 $188 Million
Q2 2023 Jul 28, 2023	SELL	$4.56 - $9.94 $172,823 - $376,726	-37,900 Reduced 0.15%	25,097,630 $187 Million
Q1 2023 May 03, 2023	BUY	$6.42 - $9.64 $2.02 Million - $3.03 Million	314,680 Added 1.27%	25,135,530 $168 Million
Q4 2022 Jan 24, 2023	BUY	$7.16 - $12.7 $23.1 Million - $41 Million	3,226,157 Added 14.94%	24,820,850 $191 Million
Q3 2022 Oct 27, 2022	SELL	$7.83 - $13.6 $86,067 - $149,491	-10,992 Reduced 0.05%	21,594,693 $230 Million
Q2 2022 Aug 08, 2022	SELL	$5.04 - $9.26 $1.89 Million - $3.48 Million	-375,919 Reduced 1.71%	21,605,685 $176 Million
Q1 2022 May 05, 2022	SELL	$6.16 - $18.03 $871,954 - $2.55 Million	-141,551 Reduced 0.64%	21,981,604 $157 Million
Q4 2021 Jan 20, 2022	BUY	$16.14 - $21.86 $997,145 - $1.35 Million	61,781 Added 0.28%	22,123,155 $379 Million
Q3 2021 Oct 19, 2021	BUY	$19.03 - $41.33 $67.4 Million - $146 Million	3,540,374 Added 19.12%	22,061,374 $508 Million
Q2 2021 Aug 02, 2021	BUY	$18.0 - $37.42 $333 Million - $693 Million	18,521,000 New	18,521,000 $676 Million

Others Institutions Holding RXRX

# of Institutions

361

Shares Held

301M

Call Options Held

7.71M

Put Options Held

4.85M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $747M
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Account

Baillie Gifford & CO Recursion Pharmaceuticals, Inc. Transaction History